157 related articles for article (PubMed ID: 12384437)
41. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Rodrigues PC; Oliveira SN; Viana MB; Matsuda EI; Nowill AE; Brandalise SR; Yunes JA
Pediatr Blood Cancer; 2007 Aug; 49(2):133-8. PubMed ID: 16883592
[TBL] [Abstract][Full Text] [Related]
42. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
43. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
44. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.
Yamada S; Hongo T; Okada S; Watanabe C; Fujii Y; Ohzeki T
Leukemia; 2001 Dec; 15(12):1892-7. PubMed ID: 11753610
[TBL] [Abstract][Full Text] [Related]
45. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
Klumper E; Pieters R; Veerman AJ; Huismans DR; Loonen AH; Hählen K; Kaspers GJ; van Wering ER; Hartmann R; Henze G
Blood; 1995 Nov; 86(10):3861-8. PubMed ID: 7579354
[TBL] [Abstract][Full Text] [Related]
46. [Prognostic significance of cytogenetic changes in patients with acute myeloid leukemia (AML). (Analysis of results in 105 patients treated at the Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000].
Jarosová M; Indrák K; Holzerová M; Hubácek J; Faber E; Papajík T; Raida L; Szotkowski T; Knotková R; Hlusí T; Jedlicková K; Pikalová Z; Sulovská I
Vnitr Lek; 2001 Sep; 47 Suppl 1():8-14. PubMed ID: 11693065
[TBL] [Abstract][Full Text] [Related]
47. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
48. Purine nucleoside analogues in the treatment of myleoid leukemias.
Robak T
Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
[TBL] [Abstract][Full Text] [Related]
49. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
Bloomfield CD; Archer KJ; Mrózek K; Lillington DM; Kaneko Y; Head DR; Dal Cin P; Raimondi SC
Genes Chromosomes Cancer; 2002 Apr; 33(4):362-78. PubMed ID: 11921271
[TBL] [Abstract][Full Text] [Related]
50. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich EJ; Estey E
Leukemia; 1995 Jun; 9(6):965-71. PubMed ID: 7596186
[TBL] [Abstract][Full Text] [Related]
51. Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Nuessler V; Schmetzer H
Eur J Haematol; 2003 Nov; 71(5):366-76. PubMed ID: 14667200
[TBL] [Abstract][Full Text] [Related]
52. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia.
Braess J; Jahns-Streubel G; Schoch C; Haase D; Haferlach T; Fiegl M; Voss S; Kern W; Schleyer E; Hiddemann W
Br J Haematol; 2001 Jun; 113(4):975-82. PubMed ID: 11442492
[TBL] [Abstract][Full Text] [Related]
53. Leukaemia cell drug resistance and prognostic factors in AML.
Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
[TBL] [Abstract][Full Text] [Related]
54. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
[TBL] [Abstract][Full Text] [Related]
55. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Dissing M; Le Beau MM; Pedersen-Bjergaard J
J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
[TBL] [Abstract][Full Text] [Related]
56. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
Joventino LP; Stock W; Lane NJ; Daly KM; Mick R; Le Beau MM; Larson RA
Leukemia; 1995 Mar; 9(3):433-9. PubMed ID: 7885042
[TBL] [Abstract][Full Text] [Related]
57. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
58. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia.
Stasi R; Del Poeta G; Masi M; Tribalto M; Venditti A; Papa G; Nicoletti B; Vernole P; Tedeschi B; Delaroche I
Cancer Genet Cytogenet; 1993 May; 67(1):28-34. PubMed ID: 8504396
[TBL] [Abstract][Full Text] [Related]
59. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
[TBL] [Abstract][Full Text] [Related]
60. Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features.
Charrin C; Belhabri A; Treille-Ritouet D; Theuil G; Magaud JP; Fiere D; Thomas X
Hematol J; 2002; 3(1):21-31. PubMed ID: 11960392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
